Sirolimus: a comprehensive review

Bibliography

• HARIHARAN S, JOHNSON CP, BRESNAHAN BA, TARANTO SE, MCINTOSH MJ, STABLEIN D: graft survival after renal transplantation in the United States, 1988 to 1996. N Engl. j Med. (2000) 342(9):605–612.
   PubMed Web of Science ®Google Scholar
• TIMONEN P, FRIEND D, ABEYWICKRAMA K, LABURTE C, VON GRAFFENRIED B, FEUTREN G: Efficacy of low-dose cyclosporin A in: results of dose-finding studies. Br. Dermatol (1990) 122 (Suppl. 36):33–39.
   Google Scholar
• FEUTREN G, MIHATSCH MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl. J. Med. (1992) 326(25):1654–1660.
   Google Scholar
• HALLORAN P, MATHEW T, TOMLANOVICH S, GROTH C, HOOFTMAN L, BARKER C: Mycophenolate mofetil in renal allograft: a pooled efficacy analysis of three randomised, double-blind, clinical studies in the prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation (1997) 63(1):39–47.
   Google Scholar
• GROTH CG, BACKMAN L, MORALESJM et al: Sirolimus (rapamyciM-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 67(7):1036–1042.
   PubMed Web of Science ®Google Scholar
• KREIS H, CISTERNE JM, LAND W et al.: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 69(7):1252–1260.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, FOR THE RAPAMUNE US STUDY GROUP: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet (2000) 356(9225):194–202.
   PubMed Web of Science ®Google Scholar
• MACDONALD AS FOR THE GLOBAL STUDY GROUP: A worldwide, Phase III, randomised, controlled, safety and efficacy study of a sirolimusicyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation (2001) 71:271–280.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, KRAMER WG: Median effect analysis of efficacy versus adverse effects of immunosuppressants.. Ther. (2001) 70(1):74–81.
   Google Scholar
• SEHGAL SN, BAKER H, VEZINA C: Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterisation.j Antibiot. (Tokyo). (1975) 28(10):727–732.
   PubMed Web of Science ®Google Scholar
• CARLSON RE BAEDER WL, CACCESE RG, WARNER LM, SEHGAL SN: Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann. NY Acad. Li. (1993) 685:86–113.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN, MOLNAR-KIMBAR K, OCAIN TD, WEICHMAN BM: Rapamycin: a novel immunosuppressive macrolide. Med. Res. Rev (1994) 14(1):1–22.
   PubMed Web of Science ®Google Scholar
• CALNE RY, COLLIER DS, LIM S et al.:Rapamycin for immunosuppression in organ allografting. Lancet (1989) 2(8656)227.
   Web of Science ®Google Scholar
• MORRIS RE, MEISER BM: Identification of a new pharmacologic action for an old compound. Med. Li. Res. (1989) 17:877–878.
   Google Scholar
• ABRAHAM RT, WIEDERRECHT GJ: Immunopharmacology of rapamycin. Ann. Rev. Immurrol. (1996) 14:483–510.
   PubMed Web of Science ®Google Scholar
• LAI JH, TAN TH: CD28 signaling causes asustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. _J. Biol. Chem. (1994) 269(48):30077–30080.
   PubMed Web of Science ®Google Scholar
• KIMBALL PM, KERMAN RK, VAN CT, LEWIS RIVI, KATZ S, KAHAN BD: Cyclosporine and rapamycin affect protein kinase C induction of the intracellular activation signal, activator of DNA replication. Transplantation (1993) 55(5):1128–1132.
   PubMed Web of Science ®Google Scholar
• KAWAMATA S, SAKAIDA H, HORT T, MAEDA M, UCHIYAMA T: The upregulation of p 27kipl by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood (1998) 92(2):561–569.
   Google Scholar
• LUO Y, MARX SO, KIYOKAWA H, KOFF A, MASSAGUE J, MARKS AR: Rapamycin resistance tied to defective regulation of p27kipl. Md. Cell Biol. (1996) 16(12):6744–6751.
   Web of Science ®Google Scholar
• HASHEMOLHOSSEINI S, NAGAMINE Y, MORLEY SJ, DESRIVIERES S, MERCEP L, FERRARI S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. I Biol. Chem. (1998) 273(23):14424–14429.
   Web of Science ®Google Scholar
• FLANAGAN WM, CRABTREE GR: Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the GUS transition. Ann. NY Acad. Sri. (1993) 696:31–37.
   PubMed Web of Science ®Google Scholar
• KUO CJ, CHUNG J, FIORENTINO DF, FLANAGAN WM, BLENIS J, CRABTREE GR: Rapamycin selectively inhibits interleukin-2 activation of p70 s6 kinase. Nature (1992) 358:70–73.
   PubMed Web of Science ®Google Scholar
• ISOTANI S, HARA K, TOKUNAGA C, INOUE H, AVRUCH J, YONEZAWA K: Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. j Biol. Chem. (1999) 274(48):34493–34498.
   PubMed Web of Science ®Google Scholar
• BRUNN GJ, HUDSON CC, SEKULIC A etal.: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 277(5322):99–101.
   Google Scholar
• VON MANTEUFFEL SR, DENNIS PB, PULLEN N, GINGRAS AC, SONENBERG N, THOMAS G: The insulin-induced signaling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol. Cell Biol. (1997) 17(9):5426–5436.
   PubMed Web of Science ®Google Scholar
• HARA K, YONEZAWA K, KOZLOWSKI MT et al.: Regulation of eIF-4E phosphorylation by mTOR. I Biol. Chem. (1997) 272(42):26457–26463.
   Web of Science ®Google Scholar
• GOTTSCHALK AR, BOISE LH, CB, QUINTANS J: Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bc1-2. Proc. Nati Acad. Sri. USA (1994) 91:7350–7354.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI T, LIU Z-J, KAWAHARA A et al.: Three distinct 11-2 signaling pathways mediated by bc/-2, c-myc, and kk cooperate in hematopoietic cell proliferation. Cell (1995) 81:223–231.
   PubMed Web of Science ®Google Scholar
• KINOSHITA T, SHIROUZU M, KAMIYA A, HASHIMOTO K, YOKOYAMA S, MIYAJIMA A: Raff MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells. Oncogene (1997) 15(6):619–627.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. (1998) 31(5):335–340.
   PubMed Web of Science ®Google Scholar
• LIU J, FARMER JD, Jr., LANE WS, FRIEDMAN J, WEISSMAN I, SCHREIBER SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 66(4):807–815.
   Google Scholar
• AMLOT PL, RAWLINGS E, ON et al.: Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation (1995) 60(7):748–756.
   PubMed Web of Science ®Google Scholar
• HONG JC, KAHAN BD: Two paradigms for new immunosuppressive strategies in organ transplantation. Cun: Opin. Organ Transplant. (1998) 3:175–182.
   Google Scholar
• KAHAN BD, NAPOLI KL, KELLY PA et al.: Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin. Transplant. (2000) 14:97–109.
   PubMed Web of Science ®Google Scholar
• SHAH VP, MIDHA KK, DIGHE S et al.:Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies.j Pharm. Li. (1992) 81:309–312.
   Google Scholar
• STREIT F, CHRISTIANS U, SCHIEBEL HM et al.: Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. (1996) 42(9):1417–1425.
   PubMed Web of Science ®Google Scholar
• DAVIS DL, MURTHY JN, NAPOLI KL et.: Comparison of steady-state trough sirolimus samples by HPLC and a radioreceptor assay. Gift]. Biochem. (2000) 33(1):31–36.
   Google Scholar
• CHRISTIANS U, SATTLER M, SCHIEBEL HM et al.: Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab. Dispos. (1992) 20(2):186–191.
   PubMed Web of Science ®Google Scholar
• WANG CP, LIM HK, CHAN KW, SCHIKSINIS RA, SCANTINA JA, SISENWINE SF: High performance liquid chromatographic isolation and spectroscopic characterisation of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally. Lig. Chromatogr. (1995) 18:2259.
   Web of Science ®Google Scholar
• SALM P, TAYLOR PJ, PILLANS P: Evaluation of a microparticle enzyme immunoassay (META) for whole blood sirolimus determination in renal transplant recipients. Ther. Drug Monti (1999) 21:442.
   Google Scholar
• KAHAN BD, CAMARDO JS: Rapamycin: Clinical results and future opportunities [Overview]. Transplantation (2001) 72(8) (In Press).
   Google Scholar
• ZIMMERMAN J, KAHAN BD: Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. j Gift]. Pharmacol. (1997) 37(5):405–415.
   Google Scholar
• KAPLAN B, MEIER-KRIESCHE HU, NAPOLI KL, KAHAN BD: The effects of relative timing of sirolimus and cyclosporine microemulsion formulation co-administration on the pharmacokinetics of each agent. Chi]. Pharmacol Ther. (1998) 63(1):48–53.
   PubMed Web of Science ®Google Scholar
• KELLY PA, WANG H, NAPOLI KL, KAHAN BD, STROBEL HW: Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. j Drug Metab. Pharmacokinet. (1999) 24(4):321–328.
   PubMed Web of Science ®Google Scholar
• RANADE AR, DONNENBERG VS, BURCKART GJ, GALANT-HAIDNER HL, KAHAN BD, DONNENBERG AD: FTY720 interactions with the p-glycoprotein pump in T cells: Preliminary observations. Am. j Transplantation (2001) 1 (Suppl. 1):217. Abstract 329.
   Google Scholar
• ZIMMERMAN JJ, PATAT A, SOUAN ML, PATY I, CADIEU G: Potential Pharmacokinetic interactions between sirolimus and tacrolimus. Am. Transplantation (2001) l\(Suppl. 1):384. Abstract 986.
   Google Scholar
• VU MD, QI S, XU D etal.: Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation (1998) 66(12):1575–1580.
   Google Scholar
• HOLT DW, OSTRAAT 0, GRINYO JM et al: MMF may be given at lower doses when used in association with sirolimus in renal transplant recipients. Am. Transplantation (2001) l\(Suppl. 1):247. Abstract 444.
   Google Scholar
• ZUCKER K, ROSEN A, TSAROUCHA A et al: Unexpected augmentation of mycophenolate acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy and analogous in vitro findings. Transpl. Immurrol (1997) 5(3):225–232.
   PubMed Web of Science ®Google Scholar
• GELDER VAN T, KLUPP J, BATERN M et al: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Monti (2001) 23:119.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, DUNN J, FITTS C et al: Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation (1995) 59(4):505–511.
   PubMed Web of Science ®Google Scholar
• KELLY PA, NAPOLI KL, DUNNE C, KAHAN BD: Conversion from liquid to solid sirolimus formulations in stable renal allograft transplant recipients. Biopharm. Drug Dispos. (1999) 20(5):249–253.
   PubMed Web of Science ®Google Scholar
• VAN BUREN C: Sirolimus oral solution and tablet formulations demonstrate equivalent safety and efficacy in renal allograft recipients. XVIII International Congress of the Transplantation Sono,. (2000). Abstract P0533:317.
   Google Scholar
• MURGIA MG, JORDAN S, KAHAN BD: The side effect profile of sirolimus: A Phase study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. (1996) 49:209–216.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, PODBIELSKI J, NAPOLI KL, KATZ SM, MEIER-KRIESCHE H-U, VAN BUREN CT: Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation (1998) 66(8):1040–1046.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, JULIAN BA, PESCOVITZ, VANRENTERGHEM Y, NEYLAN J, FOR THE RAPAMUNE STUDY GROUP: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A Phase II trial. Transplantation (1999) 68(10):1526–1532.
   PubMed Web of Science ®Google Scholar
• KAHAN BD FOR THE RAPAMUNE US AND GLOBAL STUDY GROUPS: Two-year safety and efficacy of sirolimus in renal transplantation. Am. (2001) l\(Suppl. 1):172. (Abstract 144).
   Google Scholar
• CHOU T-C, TALALAY P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul (1984) 22:27–55.
   PubMedGoogle Scholar
• ANDOH TF, LINDSLEY J, N, BENNETT WM: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation (1996) 62(3):311–316.
   PubMed Web of Science ®Google Scholar
• PODDER H, STEPKOWSKI SM, NAPOLI KL etal.: Pharmacokinetic interactions augment toxicities of sirolimus/ cyclosporine combinations. j Am. Soc. Nephrol (2001) 12:1059–1071.
   Google Scholar
• DIJOSEPH JF, SHARMA RN, CHANG JY: The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation (1992) 53:507–513.
   PubMed Web of Science ®Google Scholar
• STEPKOWSKI SM, KAHAN BD: Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc. (1991) 23(6):3262–3264.
   PubMed Web of Science ®Google Scholar
• HRICIK DE: Sirolimus improves renal function without increasing acute rejection after cyclosporine elimination in renal patients. XVIII International Congress of the Transplantation Sono,. (2000). Abstract 0430:140.
   Google Scholar
• JOHNSON R, OBERBAUER H, KREIS C, BRATTSTROM K, CLAESSON JE: Sirolimus allows early cyclosporine free immunosuppression in renal transplantation: an international trial with the tablet formulation. XVIII International Congress of the Transplantation Sono,. (2000). Abstract 0429:140.
   Google Scholar
• HONG JC, KAHAN BD: A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at high risk for delayed graft function. Transplantation (2001) 71(9):1320–1328.
   PubMed Web of Science ®Google Scholar
• HONG JC, KAHAN BD: Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation (2001) 71(10:1579–1584.
   PubMedGoogle Scholar
• PODDER H, PODBIELSKI J, HUSSEIN, KATZ SM, VAN BUREN CT, KAHAN BD: Sirolimus improves the two-year outcome or renal allografts in African-American patients. Transpl. Int. (2001) 14(3):135–142.
   PubMed Web of Science ®Google Scholar
• NEYLAN JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation (1998) 65:515–523.
   PubMed Web of Science ®Google Scholar
• ANTON HANY HS, KNAUSS TC, SEAMAN D, SIEGEL C, SCHULAK JA, HRICIK DE: Remarkable low rate of acute renal allograft rejection in African Americans receiving sirolimus, low-dose tacrolimus, and corticosteroids: prelimary results of a pilot study. Am. Transplantation (2001) 1 (Suppl. 1):173 (Abstract 148).
   Google Scholar
• MAHALATI K, KAHAN BD: A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine combination therapy. Transplant Proc. (2001) 33(1-2):1270.
   PubMed Web of Science ®Google Scholar
• VU MD, QI S, XU D etal.: Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation (1997) 64:1853–1856.
   Google Scholar
• MCALISTER VC, GAO Z, PELTEKIAN K, DOMINGUES J, MAHALATI K, MACDONALD AS: Sirolimus-tacrolimus combination immunosuppression. Lancet (2000) 355(9200:376-377. Letter.
   Google Scholar
• LANGER RIVI, VAN BUREN CT, KATZ SM, KAHAN BD: De novo hemolytic uraemic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation (In Press).
   Google Scholar
• SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl. j Med. (2000) 343(4):230–238.
   PubMed Web of Science ®Google Scholar
• SHOSKES DA, CECKA JM: Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation (1998) 66(12):1697–1701.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, FOR THE RAPAMUNE RENAL FUNCTION STUDY GROUP: therapy for high-risk renal transplant patients. Am. j Transplantation (2001) l\(Suppl. 1):184. Abstract 192.
   Google Scholar
• LINDHOLM A, KAHAN BD: Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Chi]. PharmacolTher. (1993) 54(2):205–218.
   PubMed Web of Science ®Google Scholar
• NORMAN DJ, KIMBALL JA, BENNETT WM et al: A prospective, double-blind, randomised study of high- versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Trawl. Int. (1994) 7(5):356–361.
   PubMed Web of Science ®Google Scholar
• BATIUK TD, BENNETT WM, NORMAN DJ: Cytokine nephropathy during antilymphocyte therapy. Transplant Proc. (1993) 25(2 Supp1.1):27–30.
   Google Scholar
• KAHAN BD, RAJAGOPALAN PR, HALL ML, FOR THE UNITED STATES SIMULECV RENAL STUDY GROUP: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation (1999) 67(1):276–284.
   PubMedGoogle Scholar
• NASHAN B, MOORE R, AMLOT P, SCHMIDT A-G, ABEYWICKRAMA K, SOULILLOU J-P: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet (1997) 350(9086):1193–1198.
   PubMed Web of Science ®Google Scholar
• HONG JC, KAHAN BD: Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation (1999) 68(5):701–704.
   PubMed Web of Science ®Google Scholar
• KNIGHT RJ, VAN BUREN CT, KATZ SM, KAHAN BD: Induction immunosuppression for cadaveric renal transplantation utilising sirolimus, basiliximab, and delayed introduction of cyclosporine. Am. j Transplantation (2001) l\(Suppl. 1):277. Abstract 564.
   Google Scholar
• HRICIK DE: Withdrawal of immunosuppression: implications for composite tissue allograft transplantation. Transplant Proc. (1998) 30(6):2721–2723.
   PubMed Web of Science ®Google Scholar
• KEANE WF: Lipids and progressive renal disease: the cardio-renal link. Am. j Kidney Dis. (1999) 34:xliii-xlvi.
   Google Scholar
• MORRISETT JD, ABDEL-FATTAH G, HOOGEVEEN R et al: Effects of sirolimus on plasema lipids and lipoprotein levels in renal transplant patients. (2001):In Press.
   Google Scholar
• KAHAN BD: Established drugs: Clinical and toxic effects. In: Principles, and Practice of Renal Transplantation. Kahan BD and Ponticelli C, (Eds.), Martin Dunitz, London (2000):349–414.
   Google Scholar
• HONG JC, KAHAN BD: Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation (2000) 69(10):2085–2090.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, KATZ SM, KNIGHT RJ: Outcome of 300 renal transplant recipients treated de novo with a sirolimus-cyclosporine regimen at a single center. Am. Transplantation (2001) l\(Suppl. 1):172. Abstract 145.
   Google Scholar
• NAPOLI KL, KAHAN BD: Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. I Chromatogr. B. Biomed Appl. (1994) 654(1):111.
   PubMed Web of Science ®Google Scholar
• NAPOLI KL, KAHAN BD: Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Chi]. Chem. (1996) 42(12):1943–1948.
   Google Scholar
• VAN GELDER T, HILBRANDS LB, VANRENTERGHEM Y et al.: A randomised double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 68(2):261–266.
   PubMed Web of Science ®Google Scholar
• KATZNELSON S, KOBASHIGAWA JA: Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int. Suppl (1995) 52:S112–115.
   Google Scholar
• KAHAN BD: The role of rapamycin in chronic rejection prophylaxis: a theoretical consideration. Craft (1998) 1(2 Suppl. 10:93–96.
   Google Scholar
• AKSELBAND Y, HARDING MW, NELSON PA: Rapamycin inhibits spontaneous and fibroblast growth factor B-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc. (1991) 23:2833–2836.
   PubMed Web of Science ®Google Scholar
• GRAVES LM, BORNFELDT KE, ARGAST GM et al: cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in smooth muscle cells. Proc. Natl. Acad. Sri. USA (1995) 92(16):7222–7226.
   PubMed Web of Science ®Google Scholar
• MARX SO, JAYARAMAN T, GO L et al.: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. (1995) 76:412–417.
   PubMed Web of Science ®Google Scholar
• OBATA T, KASHIWAGI A, MAEGAWA H et al.: Insulin signaling and its regulation of system A amino acid uptake in cultured rat vascular smooth muscle cells. Circ. Res. (1996) 79:1167–1176.
   PubMed Web of Science ®Google Scholar
• SCOTT PH, BELHAM CM, AL-HAFIDH J et al.: Regulatory role for cAMP in phosphatidylinositol 3-kinase/p70 ribosomal S6 kinase-mediated DNA synthesis in platelet-derived-growth-factor-stimulated bovine airway smooth-muscle cells. Biochem. J. (1996) 318(Pt 3):965–971.
   PubMedGoogle Scholar
• MOHACSI PJ, TULLER D, B etal.: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. j. Heart Lung Transplant. (1997) 16:484–492.
   Google Scholar
• SIMM A, NESTLER M, HOPPE V: PDGF-AA, a potent mitogen for cardiac fibroblasts from adult rats. j. Md. Cell CardioL (1997) 29:357–368.
   PubMed Web of Science ®Google Scholar
• GREGORY CR, HUANG X, PRATT RE et al.: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation (1995) 59(5):655–661.
   PubMed Web of Science ®Google Scholar
• GEERLING RA, DE BRUIN RWF, SCHERINGA M et al.: Suppression of acute rejection prevents graft arteriosclerosis after allogenic aorta transplantation in the rat. Transplantation (1994) 58:1258–1263.
   PubMed Web of Science ®Google Scholar
• SOUSA JE, COSTA MA, ABIZAID A et al.: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A Quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation (2001) 103:192–195.
   PubMed Web of Science ®Google Scholar
• MEISER BM, BILLINGHAM ME, MORRIS RE: Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet (1991) 338:1297–1298.
   PubMed Web of Science ®Google Scholar
• SCHMID C, HEEMANN U, TILNEY NL: Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation (1997) 64:222–228.
   PubMed Web of Science ®Google Scholar
• ALMOND PS, MATAS A, K et al.: Risk factors for chronic rejection in renal allograft recipients. Transplantation (1993) 55:752–757.
   PubMed Web of Science ®Google Scholar
• TARANTINO A. Rejection and other renal complications. In: Principles, and Practice of Renal Transplantation Kahan BD and Ponticelli C (Eds.) Martin Dunitz, London (2000):481–524.
   Google Scholar